Literature DB >> 20567660

Thyroid-associated orbitopathy.

Adel H Alsuhaibani1, Jeffrey A Nerad.   

Abstract

Thyroid-associated orbitopathy (TAO) is usually diagnosed clinically. Early presentation of TAO such as ocular irritation, lid puffiness, and mild retraction may be overlooked and misdiagnosed. Careful clinical evaluation, laboratory investigations, and orbital imaging studies are needed for diagnosing early TAO. Knowing the pathogenesis will open the door for obtaining directed and effective treatment for the inflammatory process in TAO. Most patients with mild to moderate active TAO are treated with observation alone as the available treatment modalities effective in controlling the disease have many potential side effects. Severe active TAO, compressive optic neuropathy, and severe exposure keratopathy are the main indications for treatment with immunosuppressant agents, orbital radiotherapy, or orbital decompression. Surgery remains the final rehabilitation in TAO, which should be done during cicatricial (inactive) TAO when reliable and stable results can be obtained.

Entities:  

Keywords:  Graves' ophthalmopathy; Thyroid-associated orbitopathy; lid retraction; proptosis

Year:  2007        PMID: 20567660      PMCID: PMC2884831          DOI: 10.1055/s-2007-967751

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.314


  57 in total

1.  Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors:  G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Quantitative CT of the orbit in Graves' disease.

Authors:  A Ozgen; M N Alp; M Ariyürek; N B Tütüncü; I Can; I Günalp
Journal:  Br J Radiol       Date:  1999-08       Impact factor: 3.039

3.  Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy: The 2005 ASOPRS Foundation Lecture.

Authors:  Gerald J Harris
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 Mar-Apr       Impact factor: 1.746

4.  Prevalence, natural history and surgical treatment of exophthalmos.

Authors:  D H Streeten; G H Anderson; G F Reed; P Woo
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

5.  Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.

Authors:  R M Day; F D Carroll
Journal:  Arch Ophthalmol       Date:  1968-03

6.  Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.

Authors:  G Matejka; B Vergès; G Vaillant; J M Petit; A Brun-Pacaud; S Rudoni; J M Brun
Journal:  Horm Metab Res       Date:  1998-02       Impact factor: 2.936

Review 7.  Orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Luigi Bartalena; Claudio Marcocci; Maria Laura Tanda; Roberto Rocchi; Barbara Mazzi; Giuseppe Barbesino; Aldo Pinchera
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

Review 8.  What is orbital pseudotumor?

Authors:  I Mombaerts; R Goldschmeding; R O Schlingemann; L Koornneef
Journal:  Surv Ophthalmol       Date:  1996 Jul-Aug       Impact factor: 6.048

9.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

10.  Balanced orbital decompression for Graves' ophthalmopathy.

Authors:  K G Shepard; P S Levin; D J Terris
Journal:  Laryngoscope       Date:  1998-11       Impact factor: 3.325

View more
  2 in total

1.  An abscess causing a delayed optic neuropathy after decompression for thyroid eye disease.

Authors:  Rakesh M Patel; Vinay K Aakalu; Stephanie Joe; Pete Setabutr
Journal:  Orbit       Date:  2013-10-21

2.  Elevated pulse pressure correlated with reduced retinal peripapillary capillary in thyroid-associated ophthalmology with visual field defect.

Authors:  Jie Ye; Weijie Liu; Xiaozhou Hu; Hongxiao Jiang; Mingna Xu; Haochen Jin; Mengting Wang; Zihui Liu; Qi Chen; Wencan Wu; Yunhai Tu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.